<DOC>
	<DOCNO>NCT00772928</DOCNO>
	<brief_summary>This study design evaluate controlled manner effect Prevnar® immune response Pentacel™ Primary Objective - Stage I : To compare immune response elicit infant series Pentacel™ give different time concurrently Pneumococcal conjugate vaccine ( Prevnar® ) . Primary Objective - Stage II : To compare immune response elicit 4th dose Pentacel™ give different time concurrently Prevnar® .</brief_summary>
	<brief_title>Study Effect Pneumococcal Conjugate Vaccine ( PCV ) Immunogenicity Pentacel™</brief_title>
	<detailed_description>This 2-staged study . Stage I study design compare immune response elicit infant series ( 3 dos ) Pentacel™ give different time concurrently Prevnar® . Stage II design describe immune response elicit 4th dose Pentacel™ ( antigen ) give different time concurrently Prevnar® .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria : Healthy infant 2 month ( ≥ 42 day ≤ 89 day ) age . Infants least 36 week gestation delivery . Must receive 1 dose Hepatitis B vaccine ( dose least 15 day administration study vaccine ) . Able attend schedule visit comply study procedure . Parent legal guardian willing take rectal temperature infant series . Parent legal guardian access telephone . Signed informed consent parent legal guardian obtain 1st study intervention . Able obtain least 1.5 mL blood sample prior Dose 1 . Exclusion Criteria : Clinically significant finding review system ( determined investigator subinvestigator sufficient exclusion ) . Known suspected hypersensitivity component study vaccine administer . Known suspected impairment immunologic function receipt immunosuppressive therapy immunoglobulin since birth . Known Human Immunodeficiency Virus ( HIV ) positive mother child . Personal immediate family history congenital immune deficiency . Developmental delay neurologic disorder . Chronic medical , congenital , developmental disease . Participation clinical trial . Any condition , opinion investigator , would interfere evaluation vaccine pose health risk subject . Prior history receive Acellular Pertussis ( DTaP ) Whole Cell Pertussis ( DTwP ) base combination vaccine , Haemophilus influenzae Type b ( Hib ) conjugate , Poliovirus , Pneumococcal conjugate vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Whooping cough</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Poliovirus Types 1 , 2 , 3 .</keyword>
</DOC>